Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
Melanoma
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...
CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma
CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...